LCB 69
Alternative Names: LCB-69Latest Information Update: 08 Jan 2025
At a glance
- Originator LegoChem Biosciences; Takeda
- Developer LigaChem Biosciences; Takeda
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 21 Sep 2022 Early research in Haematological malignancies in South Korea (Parenteral) (LegoChem Biosciences pipeline, September 2022)
- 21 Sep 2022 Early research in Solid tumours in South Korea (Parenteral) (LegoChem Biosciences pipeline, September 2022)
- 17 Dec 2021 Early research in Solid tumours is underway in South Korea (Lego Biosciences pipeline, December 2021)